cytochrome P450 family 2 subfamily C member 19 ; Homo sapiens

2680 Article(s)
Pub. Date
#Total Relationship(s)
1 115475 On the possible in vitro use of perfluoro compounds as oxygen reservoir for the microsomal monooxygenase system. Biochem Pharmacol 1979 Sep 15 2
2 1306117 Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. Pharmacogenetics 1992 Aug 1
3 1785203 Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica 1991 Dec 2
4 4402992 A study of the interaction of a series of substituted barbituric acids with the hepatic microsomal monooxygenase. Arch Biochem Biophys 1972 Aug 1
5 7358923 Bioorganotin chemistry. Microsomal monooxygenase and mammalian metabolism of cyclohexyltin compounds including the miticide cyhexatin. J Agric Food Chem 1980 Jan-Feb 2
6 7362648 The interaction of aliphatic nitro compounds with the liver microsomal monooxygenase system. Biochem Pharmacol 1980 Feb 1
7 7550968 High-performance liquid chromatographic determination of urinary 4'-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J Chromatogr B Biomed Appl 1995 Jun 9 1
8 7554698 Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995 Sep 10
9 7554701 Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995 Sep 2
10 7581498 The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995 3
11 7604218 [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism]. Sheng Li Ke Xue Jin Zhan 1995 Jan 2
12 7622807 Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995 Mar 1
13 7628184 Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995 Jul 2
14 7628802 [Studies on PCB toxicity involving 2C subfamily cytochrome P450]. Fukuoka Igaku Zasshi 1995 May 3
15 7640152 The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol 1995 Apr 7
16 7648765 Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther 1995 Aug 2
17 7663530 The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995 Apr 1
18 7669487 Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995 May 2
19 7704034 Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994 Dec 2
20 7720517 Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995 Jan 1
21 7781265 Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995 Jun 1
22 7781266 The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995 Jun 3
23 7781267 Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995 Jun 6
24 7870052 Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995 Feb 1
25 7969038 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 Oct 2
26 8013282 The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994 Mar-Apr 1
27 8195181 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 Jun 3 1
28 8198931 The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994 Mar 2
29 8215410 Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993 Oct 1
30 8274418 Cortisol metabolism in vitro--III. Inhibition of microsomal 6 beta-hydroxylase and cytosolic 4-ene-reductase. J Steroid Biochem Mol Biol 1993 Dec 1
31 8331574 Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 1993 Jul 3
32 8521680 Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995 Sep 9
33 8550990 Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995 Sep 2
34 8563772 A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics 1995 Oct 2
35 8582117 Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995 Nov 1
36 8587855 Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995 Nov-Dec 4
37 8613906 Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996 Apr 2
38 8627562 Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996 May 4
39 8647857 Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. J Biol Chem 1996 May 24 1
40 8653993 Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996 Mar 4
41 8653995 Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996 Mar 6
42 8681489 Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996 Jun 1
43 8698676 Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996 1
44 8703653 The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995 Nov 1
45 8712396 Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996 Jan 1
46 8730982 Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 1996 Apr 1
47 8737964 Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacol Toxicol 1996 May 2
48 8747407 Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995 Dec 2
49 8791779 Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996 1
50 8806399 Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995 5